Author Question: What schedule of peak expiratory flow rate assessment would you recommend for a home care asthmatic ... (Read 40 times)

Chloeellawright

  • Hero Member
  • *****
  • Posts: 588
What schedule of peak expiratory flow rate assessment would you recommend for a home care asthmatic patient?
 
  a. 1 to 2 times daily (on rising and at bed-time)
  b. Once per day (on rising or at bedtime)
  c. 3 to 4 times daily (on rising, noon, 4 to 7 PM, bedtime)
  d. 1 to 2 times daily (at noon and around bedtime)

Question 2

An asthmatic patient in severe distress with wheezing and dyspnea is admitted to the emergency department and started on albuterol via small-volume jet nebulizer.
 
  Which of the following approaches would you recommend to assess this therapy for this patient?
  1. Perform arterial blood gas analysis.
  2. Continuously monitor the SpO2.
  3. Assess breath sounds and vital signs before and after each treatment.
  4. Measure peak expiratory flow rate or forced expiratory volume in 1 sec before and after each treatment.
  a. 1 and 2 only
  b. 1, 3, and 4 only
  c. 2, 3, and 4 only
  d. 1, 2, 3, and 4



perkiness

  • Sr. Member
  • ****
  • Posts: 348
Answer to Question 1

ANS: C

Answer to Question 2

ANS: D



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

After 5 years of being diagnosed with rheumatoid arthritis, one every three patients will no longer be able to work.

Did you know?

Today, nearly 8 out of 10 pregnant women living with HIV (about 1.1 million), receive antiretrovirals.

Did you know?

Nitroglycerin is used to alleviate various heart-related conditions, and it is also the chief component of dynamite (but mixed in a solid clay base to stabilize it).

Did you know?

In Eastern Europe and Russia, interferon is administered intranasally in varied doses for the common cold and influenza. It is claimed that this treatment can lower the risk of infection by as much as 60–70%.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library